Ola Landgren

Professor of Medicine

Sylvester Comprehensive Cancer Center, University of Miami

United States

Research Interests

Explore related searches

Professors in United States Professors in Immunology Immunology professors in United States

Contact this professor

Get a free first email built on one of their papers, ready for you to edit and send yourself.

Articles (14)

Year:

2024

Year:

2024

Year:

2024

Year:

2024

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2022

Year:

2021

Collaborators (5)

David Siegel

Chief, Myeloma Division

UNITED STATES

View details

David G. Coffey

Assistant Professor

University of Miami School of Medicine

UNITED STATES

View details

Hang Quach

University of Melbourne

AUSTRALIA

View details

JIN SEOK KIM

Associate Professor

Severance Hospital

SOUTH KOREA

View details

Francesco Maura

Assistant Professor

Sylvester Comprehensive Cancer Center

UNITED STATES

View details

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Ola Landgren

Research Interests

Explore related searches

Contact this professor

Articles (14)

Emerging Strategies for the Prevention of Immune Toxicities Associated with T cell–Engaging Cancer Therapies

EVIDENCE meta-analysis: evaluating minimal residual disease as an intermediate clinical end point for multiple myeloma

Dietary risk factors for monoclonal gammopathy of undetermined significance in a racially diverse population

Early detection of multiple myeloma: A first step towards a screening programme

MRD and Plasma Cell Dynamics after CAR T-cell Therapy in Myeloma

Bispecific Monoclonal Antibodies in Multiple Myeloma: Data from ASH 2022: A Podcast

Final analysis of carfilzomib, dexamethasone, and daratumumab vs carfilzomib and dexamethasone in the CANDOR study

Subgroup analysis based on cytogenetic risk in patients with relapsed or refractory multiple myeloma in the CANDOR study

T cell redirecting bispecific antibodies for multiple myeloma: emerging therapeutic strategies in a changing treatment landscape

Modern Myeloma Therapy + Sustained Minimal Residual Disease–Negative = (Functional) Cure!

Mutagenic effect of chemotherapy on sperm DNA and implications for family planning

Global Myeloma Trial Participation and Drug Access in the Era of Novel Therapies

Body mass index and risk of progression from monoclonal gammopathy of undetermined significance to multiple myeloma: Results from the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial

Diagnosed with myeloma before age 40

Collaborators (5)

David Siegel

David G. Coffey

Hang Quach

JIN SEOK KIM

Francesco Maura

Make your next move.